FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021238963> ?p ?o ?g. }

• W3021238963 abstract "Landmark trials repeatedly demonstrate that pertuzumab and trastuzumab plus standard chemotherapy have the best outcomes in human epidermal growth factor receptor 2 (HER2) positive breast cancer in the neoadjuvant, adjuvant, and metastatic setting. However, many of these multicenter landmark trials lack diversity and studied largely Caucasian populations. Our goal is to address this under-representation of minorities, and compare pathologic complete response (pCR) rates in our predominantly Hispanic population with HER2 positive breast cancer receiving the same neoadjuvant chemotherapy (NACT) at Olive View-UCLA Medical Center (OVMC) to that of pCR rates observed in the TRYPHAENA trial.For this retrospective cohort study, we compiled a list of 53 patients aged 18 and older, 52 female and 1 male, with HER2 positive breast cancer identified by fluorescence in situ hybridization treated at OVMC from December 2015 to May 2018. Our population was 57% Hispanic, 13% white, 13% Filipino, 11% Asian, 2% black, and 4% other. The complete list included patients receiving standard neoadjuvant, adjuvant, and metastatic chemotherapy regimens. We analyzed 23 female patients with HER2 positive breast cancer staged I to IIIC, receiving standard NACT (docetaxel, carboplatin, trastuzumab, and pertuzumab). Metastatic HER2 positive breast cancer patients were excluded. The primary outcome studied was pCR rates after receiving NACT. pCR was defined as the absence of invasive cancer cells from tissue samples removed after surgery. Secondary outcomes measured were side effects of chemotherapy. pCR rates and side effects were compared to TRYPHAENA. Data regarding insurance status, breast cancer detection modality, and time to seek medical attention were recorded.50% of our patients who received NACT achieved pCR. Our pCR rates mirrored those observed in the TRYPHAENA trial (51.9%). The most common side effect observed in our population was diarrhea. A higher proportion (37.5%) of our patients had liver function test (LFT) elevation compared to the TRYPHAENA trial (3.9%). Baseline LFTs were normal prior to treatment in 96% of patients. In terms of modality of detection, 70% were self-palpated, 26% were detected through routine mammography, and 4% were found incidentally. Average time from mass discovery to seeking medical attention was 3.4 months. Only 26% had medical insurance at diagnosis. Although not included in our study, 28% of our patients were initially diagnosed with stage IV metastatic disease. Conclusion: Our study found that pCR rates in our primarily Hispanic population compared well to the response rates observed in landmark trials with largely Caucasian populations. Genetic variations in chemo-sensitivity may have a minimal influence on cancer care outcomes in this population." @default.
• W3021238963 created "2020-05-13" @default.
• W3021238963 creator A5015920901 @default.
• W3021238963 creator A5017057419 @default.
• W3021238963 creator A5032371921 @default.
• W3021238963 date "2020-05-02" @default.
• W3021238963 modified "2023-09-25" @default.
• W3021238963 title "Retrospective Analysis of HER2+ Breast Cancer Outcomes at a County Hospital: Do Published Outcomes Hold up in the Real World?" @default.
• W3021238963 cites W1993114978 @default.
• W3021238963 cites W2080594178 @default.
• W3021238963 cites W2095861620 @default.
• W3021238963 cites W2105874372 @default.
• W3021238963 cites W2120065707 @default.
• W3021238963 cites W2123591186 @default.
• W3021238963 cites W2166199281 @default.
• W3021238963 cites W2173764926 @default.
• W3021238963 cites W2181117014 @default.
• W3021238963 cites W2599771544 @default.
• W3021238963 cites W2624590002 @default.
• W3021238963 cites W2791673281 @default.
• W3021238963 doi "https://doi.org/10.7759/cureus.7937" @default.
• W3021238963 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7266367" @default.
• W3021238963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32499977" @default.
• W3021238963 hasPublicationYear "2020" @default.
• W3021238963 type Work @default.
• W3021238963 sameAs 3021238963 @default.
• W3021238963 citedByCount "0" @default.
• W3021238963 crossrefType "journal-article" @default.
• W3021238963 hasAuthorship W3021238963A5015920901 @default.
• W3021238963 hasAuthorship W3021238963A5017057419 @default.
• W3021238963 hasAuthorship W3021238963A5032371921 @default.
• W3021238963 hasBestOaLocation W30212389631 @default.
• W3021238963 hasConcept C121608353 @default.
• W3021238963 hasConcept C126322002 @default.
• W3021238963 hasConcept C143998085 @default.
• W3021238963 hasConcept C167135981 @default.
• W3021238963 hasConcept C2775930923 @default.
• W3021238963 hasConcept C2776694085 @default.
• W3021238963 hasConcept C2777329042 @default.
• W3021238963 hasConcept C2778239845 @default.
• W3021238963 hasConcept C2779786085 @default.
• W3021238963 hasConcept C2781164504 @default.
• W3021238963 hasConcept C2781190966 @default.
• W3021238963 hasConcept C2781451048 @default.
• W3021238963 hasConcept C2908647359 @default.
• W3021238963 hasConcept C530470458 @default.
• W3021238963 hasConcept C71924100 @default.
• W3021238963 hasConcept C99454951 @default.
• W3021238963 hasConceptScore W3021238963C121608353 @default.
• W3021238963 hasConceptScore W3021238963C126322002 @default.
• W3021238963 hasConceptScore W3021238963C143998085 @default.
• W3021238963 hasConceptScore W3021238963C167135981 @default.
• W3021238963 hasConceptScore W3021238963C2775930923 @default.
• W3021238963 hasConceptScore W3021238963C2776694085 @default.
• W3021238963 hasConceptScore W3021238963C2777329042 @default.
• W3021238963 hasConceptScore W3021238963C2778239845 @default.
• W3021238963 hasConceptScore W3021238963C2779786085 @default.
• W3021238963 hasConceptScore W3021238963C2781164504 @default.
• W3021238963 hasConceptScore W3021238963C2781190966 @default.
• W3021238963 hasConceptScore W3021238963C2781451048 @default.
• W3021238963 hasConceptScore W3021238963C2908647359 @default.
• W3021238963 hasConceptScore W3021238963C530470458 @default.
• W3021238963 hasConceptScore W3021238963C71924100 @default.
• W3021238963 hasConceptScore W3021238963C99454951 @default.
• W3021238963 hasLocation W30212389631 @default.
• W3021238963 hasLocation W30212389632 @default.
• W3021238963 hasLocation W30212389633 @default.
• W3021238963 hasLocation W30212389634 @default.
• W3021238963 hasOpenAccess W3021238963 @default.
• W3021238963 hasPrimaryLocation W30212389631 @default.
• W3021238963 hasRelatedWork W228818084 @default.
• W3021238963 hasRelatedWork W2470053459 @default.
• W3021238963 hasRelatedWork W2727568273 @default.
• W3021238963 hasRelatedWork W2778335622 @default.
• W3021238963 hasRelatedWork W2998878522 @default.
• W3021238963 hasRelatedWork W3000605535 @default.
• W3021238963 hasRelatedWork W3026789962 @default.
• W3021238963 hasRelatedWork W3030537051 @default.
• W3021238963 hasRelatedWork W3033955709 @default.
• W3021238963 hasRelatedWork W4206213581 @default.
• W3021238963 isParatext "false" @default.
• W3021238963 isRetracted "false" @default.
• W3021238963 magId "3021238963" @default.
• W3021238963 workType "article" @default.